Press-release for stocks related to approval for amneal pharmaceuticals, inc.

Prices are updated after-hours

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| -11.04% | O: 0.0% H: 0.33% C: -2.64%
fda approval

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 41.36% | O: 3.14% H: 0.0% C: -6.09%
fda approval injection

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 41.36% | O: 3.14% H: 0.0% C: -6.09%
fda approval

| 74.19% | O: -2.26% H: 0.66% C: 0.66%
xyrem fda authorized approval

Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
Published: 2023-06-14 (Crawled : 22:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 109.3% | O: 2.33% H: 4.17% C: 1.14%
rtu fda approval

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
Published: 2022-12-20 (Crawled : 17:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 150.0% | O: -0.46% H: 0.47% C: -2.33%
approval injection

Amneal Receives FDA Approval for Leuprolide Acetate Injection
Published: 2022-11-02 (Crawled : 12:20) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 131.76% | O: 0.86% H: 0.0% C: -10.21%
fda approval injection

Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
Published: 2022-05-31 (Crawled : 21:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 56.07% | O: -0.87% H: 0.0% C: 0.0%
fylnetra biosimilar approval

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
Published: 2022-05-27 (Crawled : 11:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 56.3% | O: 1.88% H: 0.71% C: -1.7%
biosimilar approval

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Published: 2022-04-13 (Crawled : 21:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 25.87% | O: -0.7% H: 6.46% C: 1.88%
alymsys approval

Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
Published: 2022-03-02 (Crawled : 19:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 17.9% | O: -7.42% H: 1.89% C: -5.19%
approval bioscience hiv biosimilar

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Published: 2022-03-01 (Crawled : 22:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 19.21% | O: 1.1% H: 0.0% C: 0.0%
approval biosimilar

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Published: 2021-11-19 (Crawled : 14:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

| 17.65% | O: -1.31% H: 4.08% C: 1.99%
approval ophthalmic emulsion

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
Published: 2021-10-27 (Crawled : 14:15) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M